GlassScriptPhysician profile
Gregory W Berger
NPI 1609406453
$3,579.06
in general payments reported to CMS, 2019-2025
23 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $767 · 2024: $1,639 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,579.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $707.52 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $680.77 | 2023-2025 | |
| Lilly USA, LLC | $667.62 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $274.87 | 2023-2025 | |
| Glaxosmithkline, LLC. | $193.40 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $170.22 | 2023-2025 | Rexulti |
| Lundbeck LLC | $115.03 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $106.06 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.93 | 2023-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $91.86 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Idorsia Pharmaceuticals US INC | $70.81 | 2023-2024 | Quviviq |
| Amgen INC. | $66.65 | 2023-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.85 | 2023-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $52.24 | 2024-2025 | Zoryve |
| Corcept Therapeutics | $39.49 | 2025 | Korlym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.96 | 2024-2025 | Caplyta |
| Alnylam Pharmaceuticals INC. | $30.75 | 2025 | Givlaari |
| Dexcom, INC. | $26.32 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $22.07 | 2025 | Auvelity |
| Abbott Laboratories | $21.32 | 2025 | Freestyle Libre |
| Inspire Medical Systems, INC. | $18.93 | 2023 | Inspire |
| Exact Sciences Corporation | $18.76 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $17.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.